Open AccessBauhinia purprea agglutinin ‐modified liposomes for human prostate cancer treatment
Author(s) -
Ikemoto Keisuke,
Shimizu Kosuke,
Ohashi Kento,
Takeuchi Yoshihito,
Shimizu Motohiro,
Oku Naoto
Publication year - 2016
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12839
Subject(s) - prostate cancer , liposome , peg ratio , cancer , chemistry , prostate , cancer cell , agglutinin , pharmacology , lectin , cancer research , biochemistry , medicine , finance , economics
Bauhinia purprea agglutinin ( BPA ) is a well‐known lectin that recognizes galactosyl glycoproteins and glycolipids. In the present study, we firstly found that BPA bound to human prostate cancer specimens but not to normal prostate ones. Therefore, we sought to develop BPA ‐ PEG ‐modified liposomes ( BPA ‐ PEG ‐ LP ) encapsulating anticancer drugs for the treatment of prostate cancer. We examined the tumor targetability of BPA ‐ PEG ‐ LP with human prostate cancer DU 145 cells, and observed that fluorescently labeled BPA ‐ PEG ‐ LP dominantly associated with the cells via the interaction between liposome‐surface BPA and cell‐surface galactosyl molecules. We also observed that BPA ‐ PEG ‐ LP accumulated in the prostate cancer tissue after the i.v. injection to DU 145 solid cancer‐bearing mice, and strongly bound to the cancer cells. In a therapeutic study, DU 145 solid cancer‐bearing mice were i.v. injected thrice with BPA ‐ PEG ‐ LP encapsulating doxorubicin ( BPA ‐ PEG ‐ LPDOX , 2 mg/kg/day as the DOX dosage) or PEG ‐modified liposomes encapsulating DOX ( PEG ‐ LPDOX ). As a result, BPA ‐ PEG ‐ LPDOX significantly suppressed the growth of the DU 145 cancer cells, whereas PEG ‐ LPDOX at the same dosage as DOX showed little anti‐cancer effect. The present study suggested that BPA ‐ PEG ‐ LP could be a useful drug carrier for the treatment of human prostate cancers.